Sign in
4

Changes in Ownership

Eloxx Pharmaceuticals, Inc. Filed Acc 0001193125-26-214890

President and CEO acquired 472,826 shares (option exercise)

  • President and CEO acquired 1,000,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Aggarwal Sumit · President and CEO

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2025-08-14 Exercise or conversion : show line 1 in the form +196,880 $0.00 $20 396,810 D
2025-09-19 Grant or award : show line 2 in the form +1,000,000 1,396,810 D
2026-01-24 Exercise or conversion : show line 3 in the form +15,000 1,411,810 D
2026-02-28 Exercise or conversion : show line 4 in the form +260,946 $0.15 $39,142 1,672,756 D

Table II: Derivative

16 lines
Date Transaction Shares Owned after D/I
2022-02-06 Grant or award : show line 5 in the form Stock Option (Right to Buy) +42,790 42,790 D
2024-10-16 Returned to the company : show line 6 in the form Stock Option (Right to Buy) −42,790 0 D
2024-10-16 Grant or award : show line 7 in the form Stock Option (Right to Buy) +42,790 42,790 D
2024-10-16 Returned to the company : show line 8 in the form Stock Option (Right to Buy) −35,580 0 D
2024-10-16 Grant or award : show line 9 in the form Stock Option (Right to Buy) +35,580 35,580 D
2024-10-16 Returned to the company : show line 10 in the form Stock Option (Right to Buy) −24,810 0 D
2024-10-16 Grant or award : show line 11 in the form Stock Option (Right to Buy) +24,810 24,810 D
2024-10-16 Returned to the company : show line 12 in the form Stock Option (Right to Buy) −68,700 0 D
Loading xslF345X06/ownership.xml…